Protein Therapeutics Market Growth Analysis | 2022-2028

Market Insights

The Protein Therapeutics Market was estimated at US$ 117.4 billion in 2021 and is expected to grow at a CAGR of 7.06% during 2022-2028 to reach US$ 190.1 billion in 2028.

Wish to get a free sample? Register Here

What are Protein Therapeutics?

Protein-based therapies made synthetically are referred to as protein therapeutics. They are strong, quick-acting medications that give the body a precise dosage of tiny protein molecules. They often include recombinant versions of naturally occurring proteins such as human growth hormones (HGH), follicle-stimulating hormones, insulin, fusion proteins, erythropoietin, monoclonal antibodies, and insulin. They support the treatment of long-term medical conditions such as cancer, diabetes, neurodegenerative diseases, and autoimmune, hematological, hormonal, and genetic illnesses. Protein therapies that are delivered orally, intravenously, or through combination therapy are also used.

Market Dynamics

One of the major factors propelling the market for protein therapies is the rising incidence of chronic illnesses. In accordance with this, the general public's growing understanding of the advantages of protein therapies, such as their low risk of side effects and high efficacy, is fostering the expansion of the market. Pharmaceutical companies use protein therapies for drug discovery and development, and monoclonal antibodies are the subject of extensive research and are used to treat a variety of viral and bacterial disorders.

The development of plasma-derived medicines and the rise in the prevalence of chronic diseases are the two main factors driving market growth for protein therapeutics. The demand for protein treatments is anticipated to rise as the prevalence of various diseases such as cancer, metabolic disorders, genetic disorders, and immunological diseases rises. A leading cause of death globally, cancer is also predicted to considerably rise in the next years, according to the World Health Organization (WHO). As a result, it is projected that the market for protein therapies will experience growth.

Additionally, the industry has grown due to an increase in proteomics research. Protein microarray technology enables parallel, high-throughput protein categorization. However, the high production costs needed to create therapies based on proteins are anticipated to impede market expansion. On the other hand, a significant increase in healthcare spending around the world has fueled the market for protein therapies. Protein therapies have a significant future in developing nations in the Asia-Pacific and LAMEA regions. Growing public awareness of chronic diseases and the use of proteins to treat them has prompted regulatory authorities in this region to make significant changes to the laws governing protein therapies. Over the coming years, demand for these products is anticipated to be driven by an increase in the elderly population, an increase in the number of chronic diseases, and a high demand for protein therapies. In order to meet demand, emerging countries must also concentrate on cost-effectiveness and scalability.

Covid-19 Impact

The unexpected coronavirus disease outbreak (COVID-19) is giving market participants more prospects for expansion. For instance, Molecular Partners AG, a clinical-stage biotechnology business based in Switzerland, is creating a novel family of protein therapies dubbed DARPin to prevent the growth of the virus.

Several investments/guidelines in the industry have been directed in recent years, which would boost the overall market:

• Other growth-inducing agents are being developed, including novel recombinant proteins, peptides, antibody-based medicines, and plasma proteins. Replacement therapies for hereditary and autoimmune illnesses such as dysfibrinogenemia, afibrinogenemia, and hypofibrinogenemia frequently employ these protein medicines. Additional factors are anticipated to fuel the market, such as considerable advancements in the healthcare infrastructure and extensive research and development (R&D) in the area of protein engineering.

Segments Analysis

By Product Type

The market has been segmented into monoclonal antibodies (mAbs), human insulin, erythropoietin, clotting factors, fusion protein, and others. Due to the wide range of availability, significance, and usefulness of these products in the treatment of many chronic conditions, the monoclonal antibodies segment dominated the market and is anticipated to maintain its dominance over the forecast period.

By Therapy Type

The protein therapeutics market has been divided into metabolic disorders, immunological disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others. The metabolic disorders segment dominated the market in 2021 and is anticipated to maintain its dominance throughout the forecast period. This is due to the need for high-quality medications and adaptable therapies for the treatment of diseases, particularly diabetes, which is anticipated to support the segment's growth.

By Function Type

The market is segmented into enzymatic and regulatory activity, special targeting activity, vaccines, protein diagnostics, and others.

Regional Analysis

The protein therapeutics market is broken down geographically into areas like North America, Europe, Asia-Pacific, and the Rest of the World (RoW). Some of the important geographical drivers include the presence of a sizable patient base, an increasing geriatric population, and the availability of a well-developed infrastructure for storing and keeping high-quality source plasma. Some of the other major drivers of regional expansion include rising disease prevalence and increased use of innovative therapies.

In 2021, North America held the largest worldwide market share for protein therapeutics, and it is expected to hold this position throughout the forecast period. This is ascribed to an increase in the incidence of chronic diseases, the use of cutting-edge treatments, the presence of important players, and an increase in healthcare spending in the area. However, due to an increase in R&D efforts, an increase in disposable incomes, and a rise in patient awareness of protein therapies, the Asia-Pacific region is expected to experience significant growth. India and China are additionally anticipated to see rapid CAGR growth in the Asia-Pacific protein therapeutics market.

Want to know which region offers the best growth opportunities? Register Here

Key Players

The following are the major players in the protein therapeutics market:

• Amgen Inc.
• Abbott
• Abbvie Inc.
• Baxter International Inc.
• Pfizer Inc
• Novo Nordisk A/S
• Merck & Co. Inc.
• Biogen Inc.
• Csl Behring L.L.C.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Johnson & Johnson

There is stiff competition in the protein therapeutics market. The market's leading players can concentrate on creating sophisticated urinary catheters that provide catheterization that reduces the danger of leakage and infection while preventing discomfort and resentment from urethral disorders. For example:

• In August 2018, Grifols S.A. purchased 24 plasma donation facilities run by Biotest AG in the United States. Companies are concentrating on partnerships to grow their geographical presence and product portfolio, as well as performing clinical trials to gain market share.
• Hizentra, the first and only subcutaneous immunoglobulin therapy for the treatment of chronic inflammatory demyelinating polyneuropathy, received FDA approval in March 2018 (CIDP).
• Shire Plc paid USD 32.0 billion in June 2016 to acquire Baxalta, the biopharmaceutical part of Baxter Inc. that had been spun off. In accordance with the agreement, Shire obtained the pharmaceutical line and a strong pipeline for the treatment of uncommon diseases from Baxalta.

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles, have been leveraged to gather the data. We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and industry experts to obtain both qualitative and quantitative insights.

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Customization Options

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances

Custom Research: Stratview Research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com